Integer (NYSE:ITGR) Price Target Raised to $154.00

Integer (NYSE:ITGR) had its target price increased by KeyCorp from $144.00 to $154.00 in a report released on Friday morning,Benzinga reports. KeyCorp currently has an overweight rating on the medical equipment provider’s stock.

A number of other brokerages have also recently issued reports on ITGR. Wells Fargo & Company restated an “overweight” rating and set a $160.00 target price on shares of Integer in a research report on Tuesday, December 3rd. Citigroup lifted their price objective on Integer from $130.00 to $145.00 and gave the stock a “neutral” rating in a research report on Wednesday, December 11th. Bank of America increased their target price on Integer from $135.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, October 1st. Piper Sandler reissued an “overweight” rating and issued a $140.00 price target (up from $125.00) on shares of Integer in a report on Friday, October 25th. Finally, Truist Financial increased their price objective on Integer from $147.00 to $163.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. One analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $146.56.

Integer Trading Down 0.3 %

Shares of Integer stock opened at $142.79 on Friday. The company has a 50-day moving average of $137.11 and a two-hundred day moving average of $129.71. The stock has a market cap of $4.79 billion, a PE ratio of 44.07, a price-to-earnings-growth ratio of 1.80 and a beta of 1.12. The company has a current ratio of 3.28, a quick ratio of 2.09 and a debt-to-equity ratio of 0.67. Integer has a 12-month low of $94.56 and a 12-month high of $144.22.

Integer (NYSE:ITGR) last issued its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $1.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.07. Integer had a return on equity of 11.63% and a net margin of 6.70%. The firm had revenue of $431.42 million during the quarter, compared to analysts’ expectations of $440.59 million. During the same period in the previous year, the firm posted $1.27 earnings per share. Integer’s revenue was up 8.7% on a year-over-year basis. On average, research analysts anticipate that Integer will post 5.33 EPS for the current fiscal year.

Hedge Funds Weigh In On Integer

A number of large investors have recently bought and sold shares of ITGR. Laurus Investment Counsel Inc. purchased a new position in shares of Integer in the 4th quarter worth about $5,422,000. R Squared Ltd acquired a new stake in Integer during the 4th quarter worth approximately $44,000. KBC Group NV raised its holdings in Integer by 83.3% in the fourth quarter. KBC Group NV now owns 1,598 shares of the medical equipment provider’s stock valued at $212,000 after buying an additional 726 shares during the period. Blue Trust Inc. lifted its position in Integer by 4.4% during the fourth quarter. Blue Trust Inc. now owns 1,689 shares of the medical equipment provider’s stock valued at $220,000 after buying an additional 71 shares in the last quarter. Finally, Tributary Capital Management LLC grew its stake in Integer by 0.8% during the fourth quarter. Tributary Capital Management LLC now owns 287,525 shares of the medical equipment provider’s stock worth $38,103,000 after buying an additional 2,289 shares during the period. Hedge funds and other institutional investors own 99.29% of the company’s stock.

Integer Company Profile

Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.